Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Irina Vasilyeva, Andrei Mariandyshev, Boris Kazennyy, Edita Davidaviciene, Nacer Lounis, Sofia Keim. Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis. Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018

Member's Comments

No comment yet.

Related content which might interest you: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient Source: Eur Respir J 2014; 43: 292-294 Year: 2004 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Why did they get XDR TB ? Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009